Key Highlights

  • Revenue of USD 38.43 million beat the USD 12.16 million estimate, while loss per share was USD 7.36.
  • Net loss was USD 48.1 million against USD 48.2 million, and nine-month net loss narrowed to USD 77.8 million.
  • Cash, cash equivalents and marketable securities were USD 51.2 million, and the filing includes a Going Concern note.
  • The company submitted a seralutinib NDA for pulmonary arterial hypertension in September after reacquiring worldwide rights in July.

Gossamer Bio (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, reported third quarter 2026 Revenue of USD 38.43 million, above the USD 12.16 million estimate. Loss per share was USD 7.36 against an estimated loss of USD 3.79. The filing states per-share data is adjusted retroactively for a reverse stock split.

Net loss was USD 48.1 million against USD 48.2 million a year earlier, and USD 77.8 million for the nine months against USD 123.1 million. Research and Development expense was USD 18.8 million against USD 45.5 million, a decrease of USD 26.7 million that the filing attributes mainly to lower seralutinib clinical trial costs.

Chiesi Agreement and NDA Submission

In July 2026 the company entered a rights reacquisition agreement with Chiesi and regained worldwide development and commercial rights to seralutinib. The filing states its revenue consisted of a one-time development cost reimbursement payment and ongoing cost-sharing payments, and that following termination of the collaboration agreement in July the company does not recognize further revenue under it.

The company announced topline results from the Phase 3 PROSERA study in pulmonary arterial hypertension in February 2026. After a pre-NDA meeting with the FDA in mid-June, it submitted an NDA in September 2026. The filing states that if the NDA is accepted for filing, seralutinib could be eligible for an FDA approval decision in the third quarter of 2027.

Cash, Deficit and Going Concern Note

Cash, cash equivalents and marketable securities were USD 51.2 million at September 30, 2026, and the accumulated deficit was USD 1,516.8 million. Nine-month research and development expense was USD 88.3 million against USD 125.2 million, a decrease of USD 36.8 million.

The filing states that conditions raise substantial doubt about the company's ability to continue as a going concern. It also notes the auditor's opinion on the 2025 financial statements includes an explanatory paragraph on the same subject.

Legal Disclosure and Items to Follow

The filing's Legal Proceedings item describes a putative class action, Kinnamon v. Gossamer Bio, Inc., filed on March 31, 2026 in the United States District Court for the Southern District of California against the company and certain executive officers and directors. The case number listed in the filing is 3:26-cv-2016-CAB-AHG. The matter is reported as stated in the filing and is flagged for human legal review.

The items to follow are the FDA's acceptance decision on the NDA, the cash balance and financing, the reverse split effects on per-share figures, and developments in the legal proceeding.